File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection

Title48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
Authors
Issue Date2006
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2006, v. 23 n. 8, p. 1171-1178 How to Cite?
Abstract
Background/aim: Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown. Method: We reviewed 53 hepatitis B e antigen positive Chinese patients treated with 48 weeks of pegylated interferon alpha-2a or 24 weeks of pegylated interferon alpha-2b. Sustained virological response was defined as hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL at week 72. Results: Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alpha-2a and 24 patients with 24 weeks of pegylated-interferon-alpha-2b. At the end-of-therapy, hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL were similar between the two groups of patients [9/29 (31.0%) vs. 2/24 (8.3%), respectively, P = 0.09]. At week 72, 10 of the 29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alpha-2a compared with two of the 24 patients (8.3%) treated with 24 weeks of pegylated-interferon-alpha-2b had sustained virological response (P = 0.04). By logistic analysis, 48 weeks of pegylated-interferon- alpha-2a was independently associated with sustained virological response (P = 0.04 adjusted hazards-ratio 9.37). Conclusion: Further studies are required to determine the optimal duration of therapy with pegylated interferons in chronic hepatitis B. © 2006 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/84484
ISSN
2013 Impact Factor: 5.478
2013 SCImago Journal Rankings: 2.609
ISI Accession Number ID
References

 

Author Affiliations
  1. Kwong Wah Hospital
  2. The University of Hong Kong
  3. Princess Margaret Hospital Hong Kong
  4. St. Paul's Hospital Hong Kong
  5. Alice Ho Miu Ling Nethersole Hospital
  6. Caritas Medical Centre Hong Kong
DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLai, LSWen_HK
dc.contributor.authorLam, Pen_HK
dc.contributor.authorZhang, HYen_HK
dc.contributor.authorFung, TTen_HK
dc.contributor.authorLai, STen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLeung, Nen_HK
dc.contributor.authorLau, GKKen_HK
dc.date.accessioned2010-09-06T08:53:30Z-
dc.date.available2010-09-06T08:53:30Z-
dc.date.issued2006en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2006, v. 23 n. 8, p. 1171-1178en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84484-
dc.description.abstractBackground/aim: Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown. Method: We reviewed 53 hepatitis B e antigen positive Chinese patients treated with 48 weeks of pegylated interferon alpha-2a or 24 weeks of pegylated interferon alpha-2b. Sustained virological response was defined as hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL at week 72. Results: Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alpha-2a and 24 patients with 24 weeks of pegylated-interferon-alpha-2b. At the end-of-therapy, hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL were similar between the two groups of patients [9/29 (31.0%) vs. 2/24 (8.3%), respectively, P = 0.09]. At week 72, 10 of the 29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alpha-2a compared with two of the 24 patients (8.3%) treated with 24 weeks of pegylated-interferon-alpha-2b had sustained virological response (P = 0.04). By logistic analysis, 48 weeks of pegylated-interferon- alpha-2a was independently associated with sustained virological response (P = 0.04 adjusted hazards-ratio 9.37). Conclusion: Further studies are required to determine the optimal duration of therapy with pegylated interferons in chronic hepatitis B. © 2006 Blackwell Publishing Ltd.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.title48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=23&issue=8&spage=1171&epage=1178&date=2006&atitle=48+weeks+pegylated+interferon+alpha-2a+is+superior+to+24+weeks+of+pegylated+interferon+alpha-2b+in+achieving+hepatitis+B+e+antigen+seroconversion+in+chronic+hepatitis+B+infectionen_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-2036.2006.02887.xen_HK
dc.identifier.pmid16611278en_HK
dc.identifier.scopuseid_2-s2.0-33646860152en_HK
dc.identifier.hkuros116846en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33646860152&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1171en_HK
dc.identifier.epage1178en_HK
dc.identifier.isiWOS:000236392800016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHui, CK=35082057900en_HK
dc.identifier.scopusauthoridLai, LSW=12769869000en_HK
dc.identifier.scopusauthoridLam, P=16151746100en_HK
dc.identifier.scopusauthoridZhang, HY=8965962000en_HK
dc.identifier.scopusauthoridFung, TT=13612072400en_HK
dc.identifier.scopusauthoridLai, ST=7402937038en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLeung, N=26643107200en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.citeulike571350-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats